Concepedia

Author

John Tomayko

GlaxoSmithKline (United States)

Also Known As

J F Tomayko, J. F. Tomayko, John F Tomayko, John F. Tomayko, John Tomayko

26

Publications

1K

Citations

15

H-Index

33

Concepts

All Affiliations

GlaxoSmithKline (United States)GlaxoSmithKline (United Kingdom)Texas Medical CenterResearch Triangle Park FoundationPfizer (United States)
JT

About

John Tomayko is an author at GlaxoSmithKline (United States) specializing in medicine, infection control, and antimicrobial resistance.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

624

2

Health Sciences

4

4

454

3

Biology

1

1

20

4

Epidemiology

1

1

57

5

Gastroenterology

1

1

280

John Tomayko

×

13

Publications

829

Citations

13

H-Index

YearCitations

Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States

Teresa M. Coque, John Tomayko, Steven C. Ricke,

Antimicrobial Agents and Chemotherapy

1996

280

A comprehensive regulatory framework to address the unmet need for new antibacterial treatments

John Rex, Barry I. Eisenstein, Jeff Alder,

The Lancet Infectious Diseases

2013

119

Bacterial Resistance to Leucyl-tRNA Synthetase Inhibitor GSK2251052 Develops during Treatment of Complicated Urinary Tract Infections

Karen O’Dwyer, Aaron Spivak, Karen Ingraham,

Antimicrobial Agents and Chemotherapy

2014

97

Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: Results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial

R. Phillip Dellinger, John Tomayko, Derek C. Angus,

Critical Care Medicine

2009

76

Analysis of Enterococcus faecalis isolates from intercontinental sources by multilocus enzyme electrophoresis and pulsed-field gel electrophoresis

John Tomayko, B E Murray

Journal of Clinical Microbiology

1995

57

Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects

Paul B. Eckburg, Troy Lister, Susannah M. Walpole,

Antimicrobial Agents and Chemotherapy

2019

50

Comparison of the beta-lactamase gene cluster in clonally distinct strains of Enterococcus faecalis

John Tomayko, K K Zscheck, Kavindra V. Singh,

Antimicrobial Agents and Chemotherapy

1996

32

Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci

Volkan Korten, John Tomayko, Barbara E. Murray

Antimicrobial Agents and Chemotherapy

1994

26

Disposition and Metabolism of GSK2251052 in Humans: A Novel Boron-Containing Antibiotic

Gary D. Bowers, David M. Tenero, Parul Patel,

Drug Metabolism and Disposition

2013

24

Chromosomal DNA restriction endonuclease digestion patterns of beta-lactamase-producing Enterococcus faecalis isolates collected from a single hospital over a 7-year period

Prema Seetulsingh, John Tomayko, P E Coudron,

Journal of Clinical Microbiology

1996

20

Page 1